The global cancer market is expected to reach $111 billion by 2020, according to new market research, with immunotherapies—particularly in lung cancer—expected to drive growth.
Doctors want the National Health Service to allow them to prescribe the oncology drug for wet age-related macular degeneration.
An NIH study shows possible limit to Lucentis's appeal.
FDA approves Eisai's thryoid cancer drug two months early, Gilead and Germany agree to a Sovaldi price cut, and Valeant looks set to make a bid for Salix.
AARP researchers found that the celebrity's decision to go public triggered a surge in genetic screening.
Hospira is planning a Lucentis biosimilar, Roche is expanding is cancer diagnostics portfolio, and cholesterol may not be as bad as originally thought (but smoking is worse than ever).
A survey showed patients are not really clear on what causes cancer.
The FDA approved the breast cancer drug Tuesday afternoon. Estimated peak sales: $3.8 billion.
The drugmaker says its Trulicity focus now includes primary care doctors in addition to specialists, and that foreign exchange will take a bite out of 2015 performance.
Obama's precision medicine initiative looks set for bipartisan support, Valeant has offered $296 million to buy Dendreon and researchers say Roche's Tamiflu works.
The label will now include Waldenstrom's macroglubulinemia.
Amgen execs assert there is still a future for 15-year-old Enbrel, Novartis sees off-label Avastin use pinch Lucentis sales and BMS has expanded its field force in anticipation of an Opdivo push.
AstraZeneca's Nexium now has generic competition, toxicity worries researchers about new cancer approaches and a former Pfizer exec will now lead an e-cigarette company.
Two new classes of medicines have shown unparalleled efficacy in oncology, but there are growing concerns about the treatments' safety.
News flowing from Bristol-Myers Squibb and Merck show the two companies may fight for elbow room among lung cancer patients with drugs that have already started building credibility in other indications.
The FDA told Pfizer that it isn't bothering with a committee review for the experimental breast cancer drug Ibrance (palbociclib). The part two news exciting investors: Pfizer and the FDA are already talking labels.
The drugmaker has signed a deal with two biotechs with novel gene-sequencing capabilities.
NIH project for genome sequencing of newborns commences; remote care, next-gen. DNA sequencing top list of 2014 healthcare-market trends; WHO plans evaluation of contagious-disease response.
FDA's accelerated approval on the checkpoint inhibitor chips away at Merck's first-mover advantage in the US market.
BMS cancer drug Opdivo becomes the second PD-1 inhibitor to secure US approval ; Omnicare hit by more kickback charges; India looks to rein in pharma marketing.
Express Scripts taps AbbVie hep. C drug as exclusive option; AZ first-in-class cancer drug approved; Cubist gains OK for superbug fighter.
The drugmaker announced it will acquire OncoEthix and its oncology candidate OTX015 in a deal worth up to $365 million
Shire may bid on NPS Pharmaceuticals; Amgen says cancer drug will cost $178,000; Takeda has a new head of R&D.
Studies by Australian company Novogen are said to demonstrate, for the first time, that a drug highly effective against brain cancers has the same high potency against melanoma.
The treatment reduces risk by half compared to widely used Zelboraf.
The regulator noted in its early 2014 retrospective that it set a high mark for the number of approved rare disease drugs this year, and that insufficient information is the reason many breakthrough status requests get bounced.
United Healthcare tests an all-in-one cancer payment model, Pfizer inks a worldwide commercialization license for a human growth factor hormone, and the Commonwealth Fund grades Medicare as the program nears its 50th.
The drugmaker shared early-trial results for its PD-1 among hard-to-tread triple-negative breast cancer patients and announced an effort to see if the drug can help patients overcome treatment resistance.
Early trials of Venetoclax, formerly known as ABT-199, indicate the experimental drug execs consider an oncology cornerstone continues to show promise.
Transfer of rights to the experimental cancer drug hinges on completion of Novartis/GSK asset swap.
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.